NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) saw some unusual options trading activity on Tuesday. Stock traders acquired 7,505 call options on the stock. This represents an increase of approximately 962% compared to the average daily volume of 707 call options.
NewAmsterdam Pharma Stock Down 0.4%
NAMS traded down $0.07 during trading hours on Tuesday, hitting $19.39. 1,364,098 shares of the company’s stock were exchanged, compared to its average volume of 1,207,235. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -11.47 and a beta of 0.15. NewAmsterdam Pharma has a 1-year low of $17.90 and a 1-year high of $42.21. The stock’s 50-day moving average is $21.41 and its two-hundred day moving average is $29.12.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.33. NewAmsterdam Pharma had a negative net margin of 789.95% and a negative return on equity of 31.39%. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $8.82 million. On average, equities research analysts anticipate that NewAmsterdam Pharma will post -1.48 EPS for the current year.
Insider Transactions at NewAmsterdam Pharma
In other news, Director John W. Smither sold 1,600 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the completion of the sale, the director owned 8,760 shares of the company’s stock, valued at $221,803.20. This represents a 15.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Davidson acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average price of $22.65 per share, for a total transaction of $226,500.00. Following the completion of the acquisition, the chief executive officer owned 792,923 shares of the company’s stock, valued at $17,959,705.95. This trade represents a 1.28% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 176,846 shares of company stock valued at $4,661,919 over the last quarter. Corporate insiders own 12.74% of the company’s stock.
Hedge Funds Weigh In On NewAmsterdam Pharma
Several hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. increased its position in shares of NewAmsterdam Pharma by 6.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after acquiring an additional 1,145,128 shares during the last quarter. Maverick Capital Ltd. raised its holdings in NewAmsterdam Pharma by 15.4% during the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock worth $69,987,000 after acquiring an additional 292,176 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in NewAmsterdam Pharma by 27.1% during the third quarter. Goldman Sachs Group Inc. now owns 1,984,732 shares of the company’s stock valued at $48,269,000 after purchasing an additional 422,821 shares during the last quarter. Bank of America Corp DE boosted its position in NewAmsterdam Pharma by 84.4% during the first quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after purchasing an additional 387,698 shares during the last quarter. Finally, Jump Financial LLC boosted its position in NewAmsterdam Pharma by 147.4% during the third quarter. Jump Financial LLC now owns 357,521 shares of the company’s stock valued at $8,695,000 after purchasing an additional 213,009 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts have issued reports on NAMS shares. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, November 1st. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, October 15th. BMO Capital Markets started coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Finally, Cantor Fitzgerald lifted their target price on NewAmsterdam Pharma from $52.00 to $61.00 and gave the company an “overweight” rating in a research report on Wednesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $49.82.
Get Our Latest Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment.
See Also
- Five stocks we like better than NewAmsterdam Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
